Eden Biodesign and ImmunoBiology (ImmBio) develop next generation vaccine for the prevention of influenza
Graham Clarke, CEO of ImmBio said: "Working with Eden Biodesign will allow us to rapidly advance the next generation influenza vaccine forward towards a Clinical Trial Application and is consistent with our aggressive timelines for bringing our viral lead product to the clinic. We are delighted for the development of our leading influenza programme to be managed by Eden Biodesign at their state of the art facility in Liverpool."
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.